Objectives Radioiodine can be applied for remnant ablation in low and low to intermediate-
risk patients with differentiated thyroid cancer (DTC). A controversy still exists about the …

Objectives To compare the ablation results, therapeutic responses and adverse reactions
between a low dose (1.1 GBq) or high dose (3.7 GBq) of 131 I in low-/intermediate-risk …

Detection of residual tissue after thyroidectomy for papillary or follicular thyroid carcinoma
may be performed using diagnostic imaging with either 123I or 131I. The former is often …

Introduction It's difficult to make a scientific, evidence-based approach about the timing of
radioiodine remnant ablation (RRA) in patients with differentiated thyroid carcinomas …

In radioiodine therapy of benign thyroid disease, a reduction of radioiodine uptake is known
for consecutive administrations of 131 I, which needs to be considered in therapy planning …

155 Objectives To compare the early outcome between patients who received 100 mCi and
150 mCi for postsurgical I-131 radioiodine ablation (RAI) in differentiated thyroid carcinoma …

Objective This study aimed to compare the clinical outcomes of patients who received
radioactive iodine (RAI) ablation after undergoing thyroidectomy for intermediate-to-high-risk …

The aim of this study was to measure the radiation exposure rate from differentiated thyroid
carcinoma (DTC) patients who had received iodine-131 (131I) treatment, and to evaluate …

Background Radioiodine remnant ablation (RRA) is used to destroy residual normal thyroid
tissue after total thyroidectomy in differentiated thyroid carcinoma (DTC) patients. As 1850 …

Objective: To evaluate success rate and factors affecting the success of radioactive iodine
(RAI) ablation in low-risk of recurrence well-differentiated thyroid carcinoma patients …